LEUKEMIAS

Brexu-cel demonstrated efficacy and safety even in patients with B-cell acute lymphoblastic leukemia with central nervous system involvement.

Ponatinib improved MRD negativity and safety in Ph+ ALL patients in the PHALLcon study, supporting its role as a potent TKI despite long-term data pending.

The FDA reviews an all-oral treatment for newly diagnosed AML, combining decitabine, cedazuridine, and venetoclax, showing promising trial results.

FDA prioritizes review of revumenib for relapsed NPM1-mutant AML, highlighting a breakthrough in targeted cancer therapies.

FDA clears lonitoclax for a phase 1 trial in relapsed/refractory AML, promising improved safety and efficacy over existing therapies.

David Andorsky, MD, discusses the dose escalation design of the ASC2ESCALATE study exploring asciminib's role in chronic myeloid leukemia.

Ziftomenib shows promising results in treating relapsed/refractory NPM1-mutant AML, achieving significant remission rates and a favorable safety profile.

Ibrahim Aldoss, MD, discusses a post hoc analysis of ponatinib in patients with Philadelphia chromosome-positive acute lymphoblastic leukemia who did not achieve early MRD negativity.

Mark Litzow, MD, discusses the challenges of using immunotherapy for the treatment of acute lymphoblastic leukemia.

Ziftomenib’s FDA application for relapsed/refractory NPM1-mutant acute myeloid leukemia is supported by data from the KOMET-001 trial.

A phase 1 trial is evaluating Actimab-A, venetoclax, and ASTX-727 in frontline acute myeloid leukemia, with initial data expected later this year.

The FDA has granted AUTX-703, a first-in-class oral KAT2A/B degrader, fast track designation for the treatment of relapsed/refractory acute myelogenous leukemia.

Obecabtagene autoleucel improved outcomes in relapsed/refractory B-cell acute lymphoblastic leukemia with low-risk CAR-HEMATOTOX scores in the 1/2 FELIX trial.

The first patient with relapsed/refractory acute myeloid leukemia has received KJ-C2320, an allogeneic CAR T-cell therapy targeting CD38 and developed using the THANK-uCAR platform, in an investigator-initiated trial in China.

LYT-200 now has gained fast track designation from the FDA in acute myeloid leukemia in addition to its prior designation for recurrent or metastatic head and neck squamous cell carcinoma.

Eunice S. Wang, MD, discusses a retrospective study of 105 patients diagnosed with secondary acute myeloid leukemia.

Eunice S. Wang, MD, discusses research behind optimal therapy for acute myeloid leukemia secondary to other malignancies, particularly in patients with prior myelodysplastic syndrome.

Adverse events associated with ponatinib in CML and ALL were shown to have decreased significantly since its approval, following various risk management measures.

A phase 3 trial of uproleselan in relapsed/refractory acute myeloid leukemia failed to meet the primary overall survival end point but showed a benefit in primary refractory patients.

Fatima Tuz Zahra, MD, discusses the methods and design of a retrospective analysis of 65 patients with acute myeloid leukemia treated with oral azacitidine maintenance after achieving complete remission.

Revumenib is now an FDA-approved treatment for adult and pediatric patients with relapsed/refractory KMT2A-rearranged acute leukemia.

In the phase 2 AUGMENT-101 trial, revumenib met its primary end point by achieving a complete remission or complete remission with partial blood count recovery in relapsed/refractory NPM1-mutant acute myeloid leukemia.

The FDA approved obecabtagene autoleucel for the treatment of relapsed/refractory B-cell acute lymphoblastic leukemia.

A phase 2/3 study investigating uproleselan with standard 7+3 chemotherapy in newly diagnosed, older patients with acute myeloid leukemia did not achieve the primary end point of improved event-free survival.